Scienture Holdings, Inc. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-3673928 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6308 Benjamin Rd , Suite 708 Tampa , Florida 33634 (Address of principal executive offices) (Zip code) (800) 261-0281 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 Par Value Per Share MEDS The NASDAQ Stock Market LLC (The NASDAQ Capital Market) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “ large accelerated filer, ” “ accelerated filer, ” “ smaller reporting company, ” and “ emerging growth company ” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ There were 1,458,659 shares of the registrant’s common stock outstanding on August 9, 2024. TRxADE HEALTH, INC. FORM 10-Q For the Quarter Ended June 30, 2024 TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 PART I: FINANCIAL INFORMATION 4 ITEM 1. FINANCIAL STATEMENTS 4 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 26 ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 34 ITEM 4. CONTROLS AND PROCEDURES 34 PART II. OTHER INFORMATION 36 ITEM 1. LEGAL PROCEEDINGS 36 ITEM 1A. RISK FACTORS 36 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 37 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 37 ITEM 4. MINE SAFETY DISCLOSURES 37 ITEM 5. OTHER INFORMATION 37 ITEM 6. EXHIBITS 38 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“ Report ”), including without limitation, “ Management’s Discussion and Analysis of Financial Condition and Results of Operations, ” contains forward-looking statements, within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the Company that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company. Words such as “ expects, ” “ anticipates, ” “ targets, ” “ goals, ” “ projects, ” “ intends, ” “ plans, ” “ believes, ” “ seeks, ” “ estimates, ” variations of such words, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. These factors include, but are not limited to: ● Our limited amount of cash; ● The negative effect on our business and our ability to raise capital that is created by the fact that there is a substantial doubt about our ability to continue as a going concern; ● Risks of our operations not being profitable; ● Claims relating to alleged violations of intellectual property rights of others; ● Technical problems with our websites; ● Cybersecurity risks ● Risks relating to implementing our acquisition strategies, and, risks related to our ability to integrate the business operations of businesses that we acquire from time to time ; ● Negative effects on our operations associated with the opioid pain medication health crisis; ● Regulatory and licensing requirement risks; ● Risks related to changes in the U.S. healthcare environment; ● The status of our information systems, facilities and distribution networks; ● Risks associated with the operations of our more established competitors; ● Political uncertainty; ● Healthcare fraud; ● The potential impact of some future pandemic; ● Inflation, rising interest rates, governmental responses thereto and possible recessions caused thereby. ● Changes in laws relating to our operations; ● Privacy laws; ● System errors; ● Dependence on current management; ● Our growth strategy; ● Risks related to the disruption of management’s attention from ongoing business operations due to pursuit of requirements related to being a listed company; and ● Other factors discussed in this Quarterly Report on Form 10-Q and in Part I, Item 1A. “Risk Factors” in Part I, Item 1A. “Risk Factors” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Form 10-K for the year ended December 31, 2023. While forward-looking statements reflect our good faith beliefs, assumptions and expectations, they are not guarantees of future performance. The forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Furthermore, we disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. Moreover, because we operate in a very competitive and rapidly changing environment, new risk factors are likely to emerge from time to time. We caution investors not to place undue reliance on these forward-looking statements and urge you to carefully review the disclosures we make concerning risks in this Quarterly Report and in Part I, Item 1A. “Risk Factors” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K and Part II, Item 1A. “Risk Factors” in the Annual Report for the period ending December 31, 2023, filed with the Securities and Exchange Commission (SEC) on April 22, 2024. Readers of this Quarterly Report on Form 10-Q should also read our other periodic filings made with the SEC and other publicly filed documents for further discussion regarding such factors. 3 PART I: FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS TRxADE HEALTH, INC. Condensed Consolidated Balance Sheets June 30, 2024 and December 31, 2023 (Unaudited) June 30, December 31, 2024 2023 ASSETS Current assets: Cash $ 7,719,993 $ 314 Accounts receivable, net 13,091 - Inventory 6,439 968 Prepaid expenses 797,383 50,724 Notes receivable, related party 1,300,000 1,300,000 Other receivables 2,230,797 1,224,702 Deferred offering costs 69,444 - Current assets of discontinued operations 7,297 176,355 Total current assets 12,144,444 2,753,063 Property, plant and equipment, net 6,500 7,500 Deposits 22,039 10,531 Investments 2,500,000 - Operating lease right-of-use assets 175,550 191,216 Noncurrent assets of discontinued operations - 9,570,603 Total assets $ 14,848,533 $ 12,532,913 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable $ 726,266 $ 1,463,014 Accrued liabilities 500,454 160,214 Other current liabilities 5,441 67,831 Contingent funding liabilities - 1,246,346 Lease liability, current 32,608 32,595 Warrant liability 1,631,974 736,953 Current liabilities of discontinued operations 5,346 7,849,402 Total current liabilities 2,902,089 11,556,355 Lease liability, net of current portion 160,996 176,909 Noncurrent liabilities of discontinued operations - 257,296 Total liabilities 3,063,085 11,990,560 Commitments and contingencies (Note 16) - - Stockholders’ equity (deficit): Series A preferred stock, $ 0.00001 par value; 9,211,246 shares authorized; none issued and outstanding as of both June 30, 2024 and December 31, 2023 - - Series B preferred stock, $ 0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both June 30, 2024 and December 31, 2023 - - Series C preferred stock, $ 0.00001 par value; 1,000 shares authorized; 290 shares issued and outstanding as of both June 30, 2024 and December 31, 2023 - - Preferred stock, value - - Common stock, $ 0.00001 par value; 100,000,000 shares authorized; 1,406,348 and 905,008 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 14 9 Additional paid-in capital 38,290,315 33,788,284 Accumulated deficit ( 26,504,881 ) ( 33,245,940 ) Total stockholders’ equity 11,785,448 542,353 Total liabilities and stockholders’ equity $ 14,848,533 $ 12,532,913 The accompanying notes are an integral part of the unaudited consolidated financial statements. 4 TRxADE HEALTH, INC. Condensed Consolidated Statements Of Operations For the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited) 2024 2023 2024 2023 Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Revenues $ 18,699 $ 366,526 $ 18,699 $ 842,882 Cost of sales 19,402 299,387 19,402 719,484 Gross (loss) profit ( 703 ) 67,139 ( 703 ) 123,398 Operating expenses: Wage and salary expense 312,049 156,300 534,644 337,893 Professional fees 509,136 188,343 688,689 324,297 Accounting and legal expense 171,708 124,799 510,755 373,015 Technology expense 86,674 27,579 138,289 52,875 General and administrative 415,421 169,900 5,115,582 416,494 Total operating expenses 1,494,988 666,921 6,987,959 1,504,574 Operating loss ( 1,495,691 ) ( 599,782 ) ( 6,988,662 ) ( 1,381,176 ) Non-operating income (expense): Change in fair value of warrant liability ( 165,132 ) ( 1,448,519 ) ( 895,021 ) ( 1,368,628 ) Interest income 41,031 - 103,952 4,198 Loss on disposal of asset - - ( 374,968 ) ( 352,244 ) Interest expense ( 4,949 ) ( 180,734 ) ( 103,464 ) ( 243,126 ) Total non-operating expense ( 129,050 ) ( 1,629,253 ) ( 1,269,501 ) ( 1,959,800 ) Net loss from continuing operations ( 1,624,741 ) ( 2,229,035 ) ( 8,258,163 ) ( 3,340,976 ) Net (loss) income from discontinued operations ( 209,161 ) 254,157 27,670,294 688,145 Net (loss) income $ ( 1,833,902 ) $ ( 1,974,878 ) $ 19,412,131 $ ( 2,652,831 ) Net loss per common share from continuing operations Basic $ ( 1.16 ) $ ( 3.27 ) $ ( 6.75 ) $ ( 4.95 ) Diluted $ ( 1.16 ) $ ( 3.27 ) $ ( 6.75 ) $ ( 4.95 ) Net (loss) income per common share from discontinued operations Basic $ ( 0.15 ) $ 0.37 $ 22.60 $ 1.02 Diluted $ ( 0.15 ) $ 0.37 $ 19.02 $ 1.02 Net (loss) income per common share Basic $ ( 1.30 ) $ ( 2.90 ) $ 15.86 $ ( 3.93 ) Diluted $ ( 1.30 ) $ ( 2.90 ) $ 13.35 $ ( 3.93 ) Weighted average common shares outstanding Basic 1,406,348 681,199 1,224,337 675,143 Diluted 1,406,348 681,199 1,454,558 675,143 The accompanying notes are an integral part of the unaudited consolidated financial statements. 5 TRxADE HEALTH, INC. Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) Shares Amount Shares Amount Shares Amount Capital Deficit Subsidiaries Equity Series B Series C Common Additional Non-controlling Total Preferred Stock Preferred Stock Stock Paid-in Accumulated Interests in Stockholders’ Shares Amount Shares Amount Shares Amount Capital Deficit Subsidiaries Equity Balances at December 31, 2022 - $ - - $ - 626,247 $ 6 $ 20,482,666 $ ( 19,719,536 ) $ ( 420,269 ) $ 342,867 Common stock issued for services - - - - 14,362 - 63,486 - - 63,486 Disposition of assets, related party - - - - - - - 492,030 420,269 912,299 Warrants exercised for cash - - - - 40,116 1 6 - - 7 Options expense - - - - - - 14,434 - - 14,434 Net loss - - - - - - - ( 677,954 ) - ( 677,953 ) Balances at March 31, 2023 - - - - 680,725 7 20,560,592 ( 19,905,459 ) - 655,140 Common stock issued for services - - - - - - 15,813 - - 15,813 Warrants exercised for cash - - - - 1,795 - 1,615 - - 1,615 Options expense - - - - - - 7,783 - - 7,783 Net loss - - - - - - - ( 1,974,878 ) - ( 1,974,878 ) Balances at June 30, 2023 - $ - - $ - 682,520 $ 7 $ 20,585,803 $ ( 21,880,337 ) $ - $ ( 1,294,527 ) Balances at December 31, 2023 15,759 $ - 290 $ - 905,008 $ 9 $ 33,788,284 ( 33,245,940 ) $ - $ 542,353 Cash dividends paid ($ 8 per share) - - - - - - - ( 12,671,072 ) - ( 12,671,072 ) Common stock issued for services - - - - 470,482 5 4,450,914 - - 4,450,919 Options exercised for cash - - - - 2,371 - 9,840 - - 9,840 Warrants exercised for cash - - - - 28,487 - 16,567 - - 16,567 Options expense - - - - - - 24,266 - - 24,266 Net income - - - - - - - 21,246,033 - 21,246,033 Balances at March 31, 2024 15,759 - 290 - 1,406,348 14 38,289,871 ( 24,670,979 ) - 13,618,906 Balance 15,759 - 290 - 1,406,348 14 38,289,871 ( 24,670,979 ) - 13,618,906 Options expense - - - - - - 444 - - 444 Net loss - - - - - - - ( 1,833,902 ) - ( 1,833,902 ) Net income (loss) - - - - - - - ( 1,833,902 ) - ( 1,833,902 ) Balances at June 30, 2024 15,759 $ - 290 $ - 1,406,348 $ 14 $ 38,290,315 $ ( 26,504,881 ) $ - $ 11,785,448 Balance 15,759 $ - 290 $ - 1,406,348 $ 14 $ 38,290,315 $ ( 26,504,881 ) $ - $ 11,785,448 The accompanying notes are an integral part of the unaudited consolidated financial statements 6 TRxADE HEALTH, INC. Condensed Consolidated Statements of Cash Flows For The Six Months Ended June 30, 2024 and 2023 (Unaudited) 2024 2023 Six Months Ended June 30, 2024 2023 Cash flows from operating activities: Net loss from continuing operations $ ( 8,258,163 ) $ ( 3,340,976 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense 1,000 5,643 Change in fair value of warrant liability 895,021 1,368,628 Options expense 24,710 22,217 Common stock issued for services 4,450,919 79,299 Amortization of right-of-use assets 15,666 100,197 Changes in operating assets and liabilities: Accounts receivable, net ( 13,091 ) ( 38,761 ) Prepaid expenses and deposits ( 758,167 ) ( 3,766 ) Inventory ( 5,471 ) ( 41,677 ) Other receivables ( 1,006,095 ) - Lease liability ( 15,900 ) ( 95,915 ) Accounts payable ( 736,748 ) 180,926 Accrued liabilities 270,796 ( 219,853 ) Current liabilities ( 62,390 ) 724,561 Net cash used in operating activities from continuing operations ( 5,197,913 ) ( 1,259,477 ) Net cash (used in) provided by operating activities from discontinued operations ( 769,805 ) 656,512 Net cash used in operating activities ( 5,967,718 ) ( 602,965 ) Cash flows from investing activities: Investment in capitalized software - ( 138,875 ) Investment in securities ( 2,500,000 ) - Net cash used in investing activities from continuing operations ( 2,500,000 ) ( 138,875 ) Net cash provided by investing activities from discontinued operations 29,931,815 420,269 Net cash provided by investing activities 27,431,815 281,394 Cash flows from financing activities: Repayment of contingent liability ( 1,246,346 ) ( 870,646 ) Cash dividends paid ( 12,671,072 ) - Proceeds from sale of future revenue - 825,000 Proceeds from exercise of warrants 16,567 1,622 Proceeds from exercise of options 9,840 - Net cash used in financing activities from continuing operations ( 13,891,011 ) ( 44,024 ) Net cash used in financing activities from discontinued operations ( 5,000 ) - Net cash used in financing activities ( 13,896,011 ) ( 44,024 ) Net change in cash 7,568,086 ( 365,595 ) Cash at beginning of period 151,907 1,111,156 Cash at end of period $ 7,719,993 $ 745,561 Supplemental disclosure of cash flow information: Cash paid for interest $ - $ 243,126 Cash paid for taxes $ - $ - Non-Cash Transactions Insurance premium financed $ 198,245 $ 306,152 Deferred offering costs included in accrued expenses $ 69,444 $ - Note issued as SOSRx contribution $ - $ 500,000 Disposition of assets, related party $ - $ 492,030 The accompanying notes are an integral part of the unaudited consolidated financial statements. 7 NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Overview TRxADE HEALTH, INC. (“ we ”, “ our ”, “ Trxade ”, and the “ Company ”) owns, as of June 30, 2024, 100 % of Trxade, Inc., Integra Pharma Solutions, LLC and Bonum Health, LLC During the year ended December 31, 2023 and a portion of the quarter ended March 31, 2024, Trxade, Inc., operated a web-based market platform that enabled commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC (“IPS” d.b.a. Trxade Prime), is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS customers include all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. On January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100 % of the outstanding membership interests of the Company’s former subsidiaries, Community Specialty Pharmacy, LLC (“CSP”) and Alliance Pharma Solutions, LLC (“APS” d.b.a DelivMeds). The Company also agreed to enter into a Master Service Agreement to operate the businesses prior to closing. Additional amounts owed to the Company as a result of this Master Service Agreement totaled $ 1,075,000 as of the closing date of August 22, 2023 (see Note 3 and Note 7). Bonum Health, LLC (“Bonum Health”), was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health Hub” was launched in February 2020; however, the Company does not anticipate installations moving forward. The Company is in the process of dissolving Bonum Health, Inc. and Bonum Health, LLC and those entities are each dissolved in the second quarter of 2024. Superlatus Merger On July 14, 2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”) and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”). 8 On July 31, 2023, the Company completed its acquisition of Superlatus in accordance with the terms and conditions of the Merger Agreement (the “Superlatus Merger”), pursuant to which the Company acquired Superlatus by way of a merger of the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the Superlatus Merger. Under the terms of the Merger Agreement, at the closing of the Superlatus Merger (the “Closing”), shareholders of Superlatus received in aggregate 136,441 shares of common stock of the Company, representing 19.99 % of the then total issued and outstanding common stock of the Company after the consummation of the Superlatus Merger and 306,855 shares of Company’s Series B Preferred Stock, par value $ 0.00001 per share (the “Series B Preferred Stock”), with a conversion ratio of 100 shares of Series B Preferred Stock to one share of common stock. At Closing, the value of the common stock was $ 7.30 per share, resulting in a total value of $ 225,000,169 . Upon consummation of the Superlatus Merger, the Company continued to trade under the current ticker symbol “MEDS.” Not all of the closing conditions of the Merger Agreement were met. As a result, the Company entered into Amendment No. 1 to the Amended and Restated Agreement and Plan of Merger (the “Amendment”) on January 8, 2024. Under the terms of the Amendment, the merger consideration to the shareholders of Superlatus was adjusted to the aggregate of 136,441 shares of common stock of the Company, representing 19.99 % of the total issued and outstanding common stock of the Company after the consummation of the Superlatus Merger and 15,759 shares of Company’s Series B Preferred Stock, with a conversion ratio of 100 shares of Series B Preferred Stock to one share of common stock. At Closing, the value of the common stock was $ 7.30 per share, resulting in a total value of $ 12,500,089 . Additionally, the shareholders of Superlatus agreed to surrender back to the Company 291,096 shares of the Company’s Series B Preferred Stock. As described below, in March 2024 the Company divested of its interest in Superlatus. Dispositions On February 16, 2024, the Company, together with Trxade, Inc., and Micro Merchant Systems, Inc. (“MMS”) entered into an asset purchase agreement (the “APA”) under which MMS agreed to purchase for cash substantially all of the assets of Trxade, Inc. On February 16, 2024, the parties consummated the closing of the transactions contemplated by the APA. Trxade, Inc. operated a web-based market platform designed to enable trading among healthcare buyers and sellers of pharmaceuticals, accessories and services. The purchase price paid at closing was $ 22,660,182 . Pursuant to the terms and conditions of the APA, because MMS received $ 1,600,000 or greater in certain collections from third parties resulting from any products or services sold, or provided, by the business assets and operations acquired from Trxade, Inc. during the period ending on the four-month anniversary of the closing date, Trxade, Inc. was due an additional $ 7,500,000 payment from MMS. The Company received the $ 7,500,000 in May 2024. On March 5, 2024, the Company entered in a Stock Purchase Agreement (“SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the SPA, the Company sold all of the issued and outstanding stock of Superlatus, to the Buyer. The $ 1.00 purchase price for the stock was delivered to the Company at the closing, which occurred simultaneously with the execution of the SPA. As a result of the transaction Superlatus ceased to be a subsidiary of the Company, and the rights and assets of Superlatus together with various liabilities and obligations that were specific to Superlatus became rights and obligations of Buyer. See Note 3 for further detail on the dispositions. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements of TRxADE HEALTH, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the SEC and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on April 22, 2024. 9 In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. All significant intercompany balances and transactions have been eliminated in consolidation. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2023, as reported in the Company’s Annual Report on Form 10-K have been omitted. Use of Estimates The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from its estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected. Significant estimates for the six months ended June 30, 2024 and 2023 include the valuation of intangible assets, including goodwill, and gain (losses) on dispositions. Fair Value of Financial Instruments The carrying amounts for cash, accounts receivable, accounts payable, accrued liabilities, and other current liabilities approximate their fair value because of their short-term maturity. Stock Split Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $ 1.00 . Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The new guidance requires enhanced disclosure of significant expenses that are regularly reported to the chief operating decision maker and the nature of segment expense information used to manage operations. The new guidance is effective for all public companies for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the new standard in annual reporting period beginning after December 15, 2023 and is currently evaluating the impacts of the new guidance on its disclosure within the financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) : Improvements to Income Tax Disclosures . The new guidance requires disaggregated information about the effective tax rate reconciliation and additional information on taxes paid that meet a quantitative threshold. The new guidance is effective for public companies for annual reporting periods beginning after December 15, 2024, and for non-public companies for annual reporting periods beginning after December 15, 2025, with early adoption permitted for both. The Company will adopt the new standard in annual reporting period beginning after December 15, 2025, and is currently evaluating the impacts of the new guidance on its disclosures within the consolidated financial statements. Accounts Receivable, net On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and its related amendments using the prospective method. The new standard requires the use of a current expected credit loss impairment model to develop and recognize credit losses for financial instruments at amortized cost when the asset is first originated or acquired, and each subsequent reporting period. The Company’s receivables are from customers and are typically collected within 90 days. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Other Receivables As of June 30, 2024 and December 31, 2023, other receivables are $ 2,230,797 and $ 1,224,702 . As of June 30, 2024, other receivables primarily consist of short-term advances to Danam Health, APS and CSP. 10 Deferred Offering Costs The Company complies with the requirements of ASC 340-10-S99-1 with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of June 30, 2024, the Company has $ 69,444 capitalized deferred offering costs. Acquisitions The Company accounts for acquisitions and investments in businesses as business combinations if the target meets the definition of a business and (a) the target is a variable interest entity (“VIE”) and the Company is the target’s primary beneficiary, and therefore the Company must consolidate its financial statements, or (b) the Company acquires more than 50% of the voting interest of the target and it was not previously consolidated. The Company records business combinations using the acquisition method of accounting, which requires all the assets acquired and liabilities assumed to be recorded at fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired is recorded as goodwill. The application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized from goodwill. The fair value assigned to tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Significant assumptions and estimates include, but are not limited to, the cash flows that an asset is expected to generate in the future, the appropriate weighted-average cost of capital, and the cost savings expected to be derived from acquiring an asset, if applicable. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the Company’s financial statements may be exposed to potential impairment of the intangible assets and goodwill. If the Company’s investment involves the acquisition of an asset or group of assets that does not meet the definition of a business, the transaction is accounted for as an asset acquisition. An asset acquisition is recorded at cost, which includes capitalizing transaction costs, and does not result in the recognition of goodwill. Intangible Assets and Goodwill The Company tests indefinite-lived intangible assets for impairment on an annual basis or whenever events or changes occur that would more-likely-than not reduce the fair value of the indefinite-lived intangible asset below its carrying value between annual impairment tests. Any indefinite-lived intangible asset assessment is performed at the Company level. The Company did not record an indefinite-lived intangible asset impairment charge for the three or six months ended June 30, 2024 and 2023. Investments The Company accounts for investments that it does not control using the cost method, equity method or fair value method, as applicable. Investments in companies in which the Company owns less than a 20% equity interest and where it does not exercise significant influence over the operating and financial policies of the investee are accounted for using the cost method of accounting. The Company periodically reviews the carrying value of these investments to determine if there has been an other-than-temporary decline in fair value below carrying value. A variety of factors are considered when determining if a decline in fair value below carrying value is other-than-temporary, including, among others, the financial condition and business prospects of the investee, as well as the Company’s investment intent. Cost method investments are carried at cost, which approximates or is less than fair value. Dividends received by the Company are recognized in equity (losses) earnings of affiliates, net of tax on the consolidated statements of operations. On February 29, 2024, the Company’s wholly owned subsidiary Trxade, Inc. entered into a Subscription Agreement (the “Subscription Agreement”) with Lafayette Energy Corp., a Delaware corporation (“Lafayette”). Pursuant to the Subscription Agreement, Trxade, Inc. will, in two equal tranches, invest a total of up to $ 5,000,000 in Lafayette in exchange for up to 2,000,000 shares of Lafayette’s Series A Convertible Preferred Stock, with the second tranche becoming payable only upon Trxade, Inc.’s receipt of notice that Lafayette has successfully drilled its first oil and gas well and produced at least one hundred (100) barrels of oil. As of June 30, 2024, the Company’s investment in Lafayette was $ 2,500,000 . The Company determined there was no impairment necessary as of June 30, 2024. Income (loss) Per Common Share Basic net income per common share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted net income per common share is computed similar to basic net income per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The dilutive effect of the Company’s options and warrants is computed using the treasury stock method. As of June 30, 2024, we had 190,242 outstanding warrants to purchase shares of common stock, 15,759 shares of Series B preferred stock, 290 shares of Series C preferred stock and 23,930 options to purchase shares of common stock. The following table sets forth the computation of basic and diluted loss per share: SCHEDULE OF BASIC AND DILUTIVE LOSS PER SHARE 2024 2023 2024 2023 Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss from continuing operations $ ( 1,624,741 ) $ ( 2,229,035 ) $ ( 8,258,163 ) $ ( 3,340,976 ) Net (loss) income on discontinued operations ( 209,161 ) 254,157 27,670,294 688,145 Net (loss) income $ ( 1,833,902 ) $ ( 1,974,878 ) $ 19,412,131 $ ( 2,652,831 ) Denominator: Denominator for EPS – weighted average shares Basic 1,406,348 681,199 1,224,337 675,143 Diluted 1,406,348 681,199 1,454,558 675,143 Net loss per common share from continuing operations Basic $ ( 1.16 ) $ ( 3.27 ) $ ( 6.75 ) $ ( 4.95 ) Diluted $ ( 1.16 ) $ ( 3.27 ) $ ( 6.75 ) $ ( 4.95 ) Net loss per common share from discontinued operations Basic $ ( 0.15 ) $ 0.37 $ 22.60 $ 1.02 Diluted $ ( 0.15 ) $ 0.37 $ 19.02 $ 1.02 Net (loss) income per common share Basic $ ( 1.30 ) $ ( 2.90 ) $ 15.86 $ ( 3.93 ) Diluted $ ( 1.30 ) $ ( 2.90 ) $ 13.35 $ ( 3.93 ) 11 Income taxes The Company’s provision for income taxes was $ 0 for the three and six months ended June 30, 2024 and 2023. The income tax provisions for these six-month periods are based upon estimates of annual income (loss), annual permanent differences and statutory tax rates in the various jurisdictions in which the Company operates. For all periods presented, the Company utilized net operating loss carryforwards to offset the impact of any taxable income. The Company’s tax rate differs from the applicable statutory rates due primarily to the establishment of a valuation allowance, utilization of deferred and the effect of permanent differences and adjustments. NOTE 2 – GOING CONCERN The accompanying interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of June 30, 2024, the Company had an accumulated deficit of $ 26,504,881 . As a result of the receipt of consideration from the asset disposition by Trxade, Inc. to MMS completed in February 2024 and the receipt of the Milestone Payment in May, the Company had $ 7,719,993 in cash as of June 30, 2024. In July 2024, the Company paid a cash dividend of $ 1.50 per share, or $ 2,187,759 in the aggregate . As of the issuance date of these consolidated financial statements, the Company has approximately $ 2,295,000 in cash. We will need to raise additional capital or secure debt funding to support on-going operations, and to fund the assets and operations of any businesses or assets we acquire . The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing stockholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless Management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. NOTE 3 – ACQUISITIONS AND DISPOSITIONS Acquisitions Superlatus, Inc. On July 31, 2023, the Company entered into the Merger Agreement (see Note 1) with Superlatus (“Seller”) whereby the Company acquired 100 % of the stock of the Seller (the “Acquisition”). Superlatus includes a wholly-owned subsidiary, Sapientia. Consideration for the Acquisition consisted of (i) 136,441 shares of the Company’s common stock at a fair value of $ 7.30 per share, representing 19.99 % of the total issued and outstanding share of the Company’s common stock at Closing, and (ii) 306,855 shares of the Company’s Series B Preferred Stock, a new class of the Company’s non-voting convertible preferred stock with a conversion ratio of 100 to one. The total fair value of the common stock and Series B Preferred Stock on the Closing Date was $ 225,000,169 (“Purchase Price”). On January 8, 2024, the Company entered into Amendment No. 1 to the Agreement and Plan of Merger (the “Amendment”). Under the terms of the Amendment, the merger consideration to the shareholders of Superlatus was adjusted to an aggregate of 136,441 shares of common stock of the Company, representing 19.99 % of the total issued and outstanding common stock of the Company after the consummation of the Merger and 15,759 shares of Company’s Series B Preferred Stock, par value $ 0.00001 per share, with a conversion ratio of 100 shares of Series B Preferred Stock to one share of common stock. The total fair value of the common stock and Series B Preferred Stock on the Closing Date was adjusted to $ 12,500,089 (“Amended Purchase Price”). Additionally, the shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company’s Series B Preferred Stock received before the Amendment. The acquisition of Superlatus was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, the Company had estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. An independent valuation expert assisted the Company in determining these fair values. Accounting guidance provides that an acquirer must recognize adjustments to provisional amounts that are identified during the measurement period, which runs through July 31, 2024, in the measurement period in which the adjustment amounts are determined. The acquirer must record in the financial statements, the effect on earnings of changes in depreciation, amortization or other income effects, if any, as a result of the changes to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. Items that could be subject to adjustment include credit fair value adjustments on loans, core deposit intangible and the deferred income tax assets resulting from the acquisition. The Amended Purchase Price allocation as of the acquisition date is presented as follows: SCHEDULE OF PURCHASE PRICE ALLOCATION July 31, 2023 Purchase consideration: Common Stock, at fair value $ 996,019 Series B Preferred Stock, at fair value 11,504,070 Total purchase consideration $ 12,500,089 Purchase price allocation: Cash $ 5,546 Prepaid expenses 3,705 Inventory 122,792 Intangible assets, net 9,777,479 Goodwill 5,129,115 Assets acquired 15,038,637 Accounts payable and other current liabilities ( 283,548 ) Purchase price payable ( 350,000 ) Notes payable ( 1,905,000 ) Liabilities assumed ( 2,538,548 ) Net assets acquired $ 12,500,089 12 The Urgent Company, Inc. On September 27, 2023, the Company entered into an Asset Purchase Agreement (“APA”) with The Urgent Company, Inc. (“TUC”) and its wholly owned subsidiaries, pursuant to which, the Company was assigned certain inventory and property and equipment and assumed certain operating leases for consideration of $ 4,400,000 in promissory notes (“Purchase Price”, see Note 11). Subsequent to December 31, 2023, we divested our interest in TUC. The transaction was accounted for as an asset acquisition pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, the Company allocated the cost of the asset acquisition to the assets acquired and liabilities assumed as of the acquisition date based on their respective relative fair value as of the date of the transaction. The following summarizes the provisional relative fair values of the assets acquired as of the acquisition date based on the allocation of the cost of the asset acquisition: SCHEDULE OF FAIR VALUES OF ASSETS ACQUIRED September 27, 2023 Purchase consideration: Promissory note $ 4,400,000 Total purchase consideration $ 4,400,000 Allocation of cost of assets acquired: Inventory $ 4,168,830 Property and equipment 231,170 Assets acquired 4,400,000 Net assets acquired $ 4,400,000 Dispositions and Divestitures Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC On August 22, 2023, the Company and Wood Sage, LLC (“Wood Sage”) entered into (i) a Membership Interest Purchase Agreement, pursuant to which the Company sold its 100 % membership interest in Alliance Pharma Solutions, LLC (“ASP MIPA”) for consideration of a $ 125,000 promissory note (“ASP Sale Price”) and (ii) a Membership Interest Purchase Agreement, pursuant to which the Company sold 100 % of the membership interest in Community Specialty Pharmacy, LLC (“CSP MIPA”) in exchange for a $ 100,000 promissory note (“CSP Sale Price”). As a result, the results of APS and CSP were classified as discontinued operations in our condensed statements of operations and excluded from both continuing operations and segment results for the three months ended March 31, 2023. As part of recognizing the business as held for sale in accordance with U.S. GAAP, the Company was required to measure APS and CSP at the lower of its carrying amount or fair value less cost to sell. As a result of this analysis, during the year ended December 31, 2023, the Company recognized a non-cash, pre-tax loss on disposal of $ 3,300,225 . The loss is included in “Net loss from discontinued operations” in the consolidated statements of operations. The loss was determined by comparing the fair value of the consideration received for the sale of a 100% interest in APS and CSP with the net assets of APS and CSP, respectively, immediately prior to the transaction. As a result of the transactions, the following assets and liabilities of APS and CSP were transferred to Wood Sage as of August 22, 2023: SCHEDULE OF ASSETS AND LIABILITIES Alliance Pharma Solutions, LLC Community Specialty Pharmacy, LLC Cash $ 1,050 $ 61,988 Accounts receivable, net - 101,901 Inventory - 123,230 Prepaid assets - 525 Intangible assets and capitalized software, net 739,337 - Accounts payable ( 23,982 ) ( 231,876 ) Accrued liabilities - ( 10,182 ) Net assets sold $ 716,405 $ 45,586 Trxade, Inc. On February 16, 2024, the Company, together with Trxade, Inc., a wholly owned subsidiary of the Company, and MMS entered into an asset purchase agreement (the “APA”) under which MMS agreed to purchase for cash substantially all of the assets of Trxade, Inc. On February 16, 2024, the parties consummated the closing of the transactions contemplated by the APA. The purchase price paid at closing was $ 22,660,182 . Subject to the terms and conditions of the APA, if, during the period beginning on the closing date and ending on the four-month anniversary of the closing date, MMS received $ 1,600,000 or greater in certain collections from third parties resulting from any products or services sold, or provided, by the business assets and operations acquired from Trxade, Inc., Trxade, Inc. would receive an additional $ 7,500,000 payment from MMS (the “Milestone Payment”). The Company received the Milestone Payment in May 2024. 13 The APA was accounted for a business disposition in accordance with ASC 810-40-40-3A. As of February 16, 2024, the Company no longer consolidated the assets, liabilities, revenues and expenses of Trxade, Inc. The components of the disposition are as follows: SCHEDULE OF BUSINESS ACQUISITIONS ASSETS AND LIABILITIES Cash received from MMS $ 22,660,182 - Other receivable from MMS 7,500,000 Total fair value of consideration received $ 30,160,182 Carrying amount of assets and liabilities Cash $ 76,821 Accounts receivable, net 719,876 Prepaid expenses 55,397 Property, plant and equipment, net 45,655 Intangible assets, net Operating lease right-of-use assets 12,277 Purchase price payable Accounts payable ( 347,000 ) Accrued liabilities ( 5,269 ) Other current liabilities ( 26,244 ) Lease liability, current ( 1,556 ) Notes payable, current portion ( 45,000 ) Lease liability, net of current portion ( 10,720 ) Notes payable Total carrying amount of assets and liabilities 474,236 Gain on disposition of business $ 29,685,946 The gain on disposition of business of $ 29,685,946 was included in income from discontinued operations, net of tax in the consolidated statements of operations. Superlatus Inc. On March 5, 2024, the Company entered in a Stock Purchase Agreement (“SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the SPA, the Company sold all of the issued and outstanding stock (the “Stock”) of Superlatus to the Buyer. The purchase price for the stock was $ 1.00 which was delivered to the Company at the closing, which occurred simultaneously with the execution of the SPA. As a result of the transaction Superlatus is no longer a subsidiary of the Company, and the rights and assets of Superlatus together with various liabilities and obligations that were specific to Superlatus became rights and obligations of Buyer. The transaction was accounted for a business disposition in accordance with ASC 810-40-40-3A. As of March 5, 2024, the Company no longer consolidated the assets, liabilities, revenues and expenses of Superlatus. The components of the disposition are as follows: SCHEDULE OF BUSINESS ACQUISITIONS ASSETS AND LIABILITIES Fair value of consideration received $ 1 Total fair value of consideration received $ 1 Carrying amount of assets and liabilities Cash $ 151,546 Property, plant and equipment, net 223,080 Intangible assets, net 8,962,688 Operating lease right-of-use assets 325,995 Purchase price payable ( 350,000 ) Accounts payable ( 224,137 ) Accrued liabilities ( 173,436 ) Notes payable, current portion ( 6,480,000 ) Lease liability - current ( 105,567 ) Lease liability - net of current portion ( 221,428 ) Notes payable ( 25,000 ) Total carrying amount of assets and liabilities 2,083,743 Loss on disposition of business $ ( 2,083,742 ) The loss of disposition of business of $ 2,083,742 was included in income from discontinued operations, net of tax in the consolidated statements of operations. 14 Discontinued Operations In accordance with the provisions of ASC 205-20, the Company has excluded the results of discontinued operations from its results of continuing operations in the accompanying consolidated statements of operations for the three and six months ended June 30, 2024 and 2023. The results of the discontinued operations for the three and six months ended June 30, 2024 and 2023 consist of the following: SCHEDULE OF DISCONTINUED OPERATIONS 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 TRX Bonum Superlatus SOSRx CSP APS Total Three Months Ended Three Months Ended Three Months Ended Three Months Ended Three Months Ended Three Months Ended Three Months Ended June 30, June 30, June 30, June 30, June 30, June 30, June 30, 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Revenues $ - $ 1,556,843 $ - $ 1,896 $ - $ - $ - $ - $ - $ 325,811 $ - $ - $ - $ 1,884,550 Cost of sales - - - - - - - - - 306,962 - - - 306,962 Gross profit - 1,556,843 - 1,896 - - - - - 18,849 - - - 1,577,588 Operating expenses: Wage and salary expense 161,038 470,002 - 20,300 - - - - - 174,354 - - 161,038 664,656 Professional fees 46,775 38,462 - - - - - - - 1,444 - 1,375 46,775 41,281 Technology expense - 328,373 - 19,795 - - - - - 65,965 - 68,314 - 482,447 General and administrative 1,348 118,766 - 1,138 - - - - - 13,303 - 1,839 1,348 135,046 Total operating expenses 209,161 955,603 - 41,234 - - - - - 255,066 - 71,528 209,161 1,323,431 Operating income (loss) ( 209,161 ) 601,239 - ( 39,337 ) - - - - - ( 236,217 ) - ( 71,528 ) ( 209,161 ) 254,157 Non-operating income (expense): Gain (loss) on dispositions Total non-operating income (expense) Net income (loss) on discontinued operations $ ( 209,161 ) $ 601,239 $ - $ ( 39,337 ) $ - $ - $ - $ - $ - $ ( 236,217 ) $ - $ ( 71,528 ) $ ( 209,161 ) $ 254,157 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 TRX Bonum Superlatus SOSRx CSP APS Total Six Months Ended Six Months Ended Six Months Ended Six Months Ended Six Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, June 30, June 30, June 30, 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Revenues $ 970,808 $ 3,000,020 $ - $ 18,856 $ - $ - $ - $ - $ - $ 637,068 $ - $ - $ 970,808 $ 3,655,944 Cost of sales - - - - - - - - - 577,535 - - - 577,535 Gross profit 970,808 3,000,020 - 18,856 - - - - - 59,533 - - 970,808 3,078,408 Operating expenses: Wage and salary expense 713,021 999,329 578 42,109 - - - - - 347,525 - - 713,599 1,388,963 Professional fees 62,160 39,695 - - - - - - - 2,168 - 3,125 62,160 44,988 Technology expense 86,660 509,197 2,245 38,216 - - - - - 69,532 - 73,491 88,905 690,436 General and administrative 37,377 232,008 678 2,564 - - - 146 - 27,529 - 3,629 38,055 265,876 Total operating expenses 899,218 1,780,229 3,500 82,889 - - - 146 - 446,754 - 80,245 902,719 2,390,264 Operating income (loss) 71,590 1,219,790 ( 3,500 ) ( 64,033 ) - - - ( 146 ) - ( 387,221 ) - ( 80,245 ) 68,089 688,144 Non-operating income (expense): Gain (loss) on dispositions 29,685,946 - - - ( 2,083,742 ) - - - - - - - 27,602,204 - Total non-operating income (expense) 29,685,946 - - - ( 2,083,742 ) - - - - - - - 27,602,204 - Net income (loss) on discontinued operations $ 29,757,536 $ 1,219,790 $ ( 3,500 ) $ ( 64,033 ) $ ( 2,083,742 ) $ - $ - $ ( 146 ) $ - $ ( 387,221 ) $ - $ ( 80,245 ) $ 27,670,294 $ 688,145 In the second quarter of 2024, the Company determined to dissolve the business of Bonum, and have presented the results of operations in net income (loss) from discontinued operations. 15 NOTE 4- RELATED PARTY TRANSACTIONS On November 21, 2023, but effective September 14, 2023, the Company issued a promissory note to Danam Health, Inc. (the “Danam Note”) in the amount of $ 300,000 . Danam Health, Inc. prepaid $ 250,000 prior to the execution date. The Danam Note did not accrue interest. As of December 31, 2023, the balance of the Danam Note was $ 50,000 . The Danam Note was fully paid off in February 2024. On February 29, 2024, the Company’s wholly owned subsidiary Trxade, Inc. entered into a Subscription Agreement (the “Subscription Agreement”) with Lafayette. Pursuant to the Subscription Agreement, Trxade, Inc. will, in two equal tranches, invest a total of up to $ 5,000,000 in Lafayette in exchange for up to 2,000,000 shares of Lafayette’s newly created Series A Convertible Preferred Stock, with the second tranche becoming payable only upon Trxade, Inc.’s receipt of notice that Lafayette has successfully drilled its first oil and gas well and produced at least one hundred (100) barrels of oil. As of June 30, 2024, other receivables includes a $ 997,500 receivable from Danam Health Inc. and $ 1,203,682 receivable from APS and CSP. See Note 7 for note receivable from Wood Sage, LLC. NOTE 5 – REVENUE RECOGNITION The Company derives revenue from two primary sources—product revenue and service revenue. Product revenue consists of shipments of: ● Resale of pharmaceutical products to pharmacies; and ● Revenues for our products are recognized and invoiced when the product is shipped to the customer. Service revenue consists primarily of: ● Transaction fees from the facilitation of buyer generated purchase orders to suppliers, billed monthly; ● Data service fees associated with providing vendors of pharmaceutical products with data analysis of their catalogues and branding of their products or company to the Company’s registered buyers, billed monthly or as a one-time fee; and ● Software-as-a-Service (“SaaS”) fees for a platform for virtual healthcare provider visits, billed monthly. Revenues for the Company’s services that are billed monthly are recognized and invoiced at the beginning of the month. Revenues for one-time services are recognized at the point in time when services are rendered. Payment terms for products and services are generally 0 to 60 days and the Company has no contract assets or liabilities. The following table presents disaggregated revenue by major product categories during the three and six months ended June 30, 2024 and 2023: SCHEDULE OF DISAGGREGATED REVENUE 2024 2023 2024 2023 Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Product revenues Pharmaceutical product resale $ 18,699 $ 366,526 $ 18,699 $ 842,882 Total product revenue $ 18,699 $ 366,526 $ 18,699 $ 842,882 Total revenue $ 18,699 $ 366,526 $ 18,699 $ 842,882 NOTE 6 – INVENTORY Inventory value is determined using the weighted average cost method and is stated at the lower of cost or net realizable value. As of June 30, 2024 and December 31, 2023, inventory was comprised of the following: SCHEDULE OF INVENTORY June 30, December 31, 2024 2023 Raw materials $ - $ - Finished goods 6,439 968 Inventory $ 6,439 $ 968 NOTE 7 – NOTES RECEIVABLE – RELATED PARTY On August 22, 2023, the Company received a Promissory Note (the “Wood Sage Note”) in the amount of $ 1,300,000 from Wood Sage, LLC and entered into the APS MIPA and CSP MIPA for the Company to sell APS and CSP and entered into a Master Service Agreement (“Wood Sage MSA”). The Wood Sage Note bears no interest and is due and payable within thirty days of a change in control, as defined by the Wood Sage Note, of the borrower. As of both June 30, 2024 and December 31, 2023, the outstanding balance of the Wood Sage Note was $ 1,300,000 , respectively. 16 NOTE 8 – INTANGIBLE ASSETS The intangible assets were sold to Superlatus on March 5, 2024 per the Stock Purchase Agreement (see Note 3). NOTE 9 – OTHER CURRENT LIABILITIES As of June 30, 2024 and December 31, 2023, other current liabilities consisted of the following: SCHEDULE OF OTHER CURRENT LIABILITIES June 30, December 31, 2024 2023 Insurance refunds payable $ - $ 62,390 Other payables 5,441 5,441 Other current liabilities $ 5,441 $ 67,831 NOTE 10 – CONTINGENT FUNDING LIABILITIES On December 13, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third party agreed to fund the Company $ 150,000 to purchase $ 214,500 of future receivables. The Company also paid $ 7,500 as a one-time origination fee in connection with the Receivables Agreement. This agreement was fully paid off in February 2024. On November 22, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third party agreed to fund the Company $ 275,000 to purchase $ 393,250 of future receivables. The Company also paid $ 13,750 as a one-time origination fee in connection with the Receivables Agreement. This agreement was fully paid off in February 2024. On October 25, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third party agreed to fund the Company $ 1,200,000 to purchase $ 1,728,000 of future receivables. The Company also paid $ 60,000 as a one-time origination fee in connection with the Receivables Agreement. This agreement was fully paid off in February 2024. The Company’s relationship with the funding source meets the criteria in ASC 470-10-25 – Sales of Future Revenues or Various Other Measures of Income (“ASC 470”), which relates to cash received from a funding source in exchange for a specified percentage or amount of revenue or other measure of income of a particular product line, business segment, trademark, patent or contractual right for a defined period. Under this guidance, the Company recognized the fair value of its contingent obligation to the funding source, as of the acquisition date, as a current liability in its consolidated balance sheet. Under ASC 470, amounts recorded as debt are to be amortized under the interest method. The Company made an accounting policy election to utilize the prospective method when there is a change in the estimated future cash flows, whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining period. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield. As of June 30, 2024, and December 31, 2023, the total contingent funding liability was $ 0 and $ 1,246,346 respectively, and the effective interest rate was approximately 0 % and 31 %, respectively. This rate represents the discount rate that equates the estimated future cash flows with the fair value of the debt and is used to compute the amount of interest to be recognized each period. Any future payments made to the funding source will decrease the contingent funding liability balance accordingly. 17 NOTE 11 – NOTES PAYABLE On November 17, 2023, the Company issued promissory notes to Moku Foods, Inc. (the “Moku Foods November 2023 Note”) in the amount of $ 50,000 . The promissory note accrues interest at 11.5 % per annum, compounded monthly and is payable upon demand at any time after November 30, 2023. As of December 31, 2023, the balance of the Moku Foods November 2023 Note was $ 50,000 . The Company has accrued interest of $ 945 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On October 16, 2023, the Company issued promissory notes to Moku Foods, Inc. (the “Moku Foods October 2023 Note”) in the amount of $ 150,000 . The promissory note accrues interest at 11.5 % per annum, compounded monthly and is payable upon demand at any time after October 31, 2023. As of December 31, 2023, the balance of the Moku Foods October 2023 Note was $ 150,000 . The Company has accrued interest of $ 4,300 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On September 27, 2023, the Company issued promissory notes to Perfect Day, Inc. (the “Perfect Day Note”) in the amount of $ 4,400,000 as consideration for the TUC APA (see Note 3). The promissory notes do not accrue interest and are payable upon demand at any time after October 31, 2023. The entire aggregate, unpaid principal sum of the note is immediately due and payable upon the occurrence of a change in control, as defined in the agreement. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On September 14, 2023, the Company issued a promissory note to Danam Health, Inc. (the “Danam Note”) in the amount of $ 300,000 . The Company received a deposit of $ 200,000 on September 14, 2023, and an additional deposit of $ 100,000 on October 13, 2023. The Danam Note accrues interest at 0 % per annum and is due and payable no later than 30 days after a change in control of borrower, as defined in the note agreement. As of December 31, 2023, the balance of the Danam Note was $ 50,000 . The Danam Note was fully paid off in February 2024. On June 16, 2023, the Company issued a secured debenture to Eat Well Investment Group, Inc. (the “Eat Well June 2023 Note”) in the amount of $ 1,150,000 for the purchase of Sapientia, a wholly-owned subsidiary of Superlatus. The Eat Well June 2023 Note is secured by 100 % of the membership interests in Sapientia. The Eat Well June 2023 Note began accruing interest at 12 % per annum, compounded monthly, as of October 31, 2023. The Eat Well June 2023 Note matured on December 31, 2023 . As of December 31, 2023, the balance of the Eat Well June 2023 Note was $ 1,150,000 . The Company has accrued interest of $ 23,063 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On February 8, 2023, Sapientia, a wholly-owned subsidiary of Superlatus, entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well February 2023 Note”) in the amount of $ 25,000 . The Eat Well February 2023 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures February 7, 2025 . As of December 31, 2023, the balance of the Eat Well February 2023 Note was $ 25,000 . The Company has accrued interest of $ 418 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On September 14, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well September 2022 Note”) in the amount of $ 50,000 . The Eat Well September 2022 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures September 13, 2024 . As of December 31, 2023, the balance of the Eat Well September 2022 Note was $ 50,000 . The Company has accrued interest of $ 1,212 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On July 26, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well July 26, 2022 Note”) in the amount of $ 35,000 . The Eat Well July 26, 2022 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures July 25, 2024 . As of December 31, 2023, the balance of the Eat Well July 26, 2022 Note was $ 35,000 . The Company has accrued interest of $ 938 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. 18 On July 12, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well July 12, 2022 Note”) in the amount of $ 25,000 . The Eat Well July 12, 2022 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures July 11, 2024 . As of December 31, 2023, the balance of the Eat Well July 12, 2022 Note was $ 25,000 . The Company has accrued interest of $ 688 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On March 15, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well March 2022 Note”) in the amount of $ 100,000 . The Eat Well March 2022 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures March 14, 2024 . As of December 31, 2023, the balance of the Eat Well March 2022 Note was $ 100,000 . The Company has accrued interest of $ 3,361 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On February 1, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well February 2022 Note”) in the amount of $ 100,000 . The Eat Well February 2022 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures February 1, 2024 . As of December 31, 2023, the balance of the Eat Well February 2022 Note was $ 100,000 . The Company has accrued interest of $ 3,576 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On January 20, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well January 2022 Note”) in the amount of $ 20,000 . The Eat Well January 2022 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures January 20, 2024 . As of December 31, 2023, the balance of the Eat Well January 2022 Note was $ 20,000 . The Company has accrued interest of $ 728 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On December 24, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well December 2021 Note”) in the amount of $ 100,000 . The Eat Well December 2021 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matured December 24, 2023 . As of December 31, 2023, the balance of the Eat Well December 2021 Note was $ 100,000 . The Company has accrued interest of $ 3,776 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On November 10, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well November 2021 Note”) in the amount of $ 50,000 . The Eat Well November 2021 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matured November 10, 2023 . As of December 31, 2023, the balance of the Eat Well November 2021 Note was $ 50,000 . The Company has accrued interest of $ 2,001 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On August 18, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well August 2021 Note”) in the amount of $ 250,000 . The Eat Well August 2021 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matured August 18, 2023 . As of December 31, the balance of the Eat Well August 2021 Note was $ 250,000 . The Company has accrued interest of $ 11,079 as of December 31, 2023. On March 5, 2024, the Company entered into Stock Purchase Agreement with Superlatus Foods, Inc. whereby the Company sold of its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. 19 NOTE 12 – STOCKHOLDERS’ EQUITY Designation of Series C Preferred Stock Effective October 4, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series C Preferred Stock with the Secretary of the State of Delaware which designated 1,000 shares of the Company’s authorized and unissued preferred stock as convertible Series C Preferred Stock at a par value of $ 0.00001 per share. Hudson Global Ventures Stock Purchase Agreement On October 4, 2023, the Company entered into a Securities Purchase Agreement (“Agreement”, or “SPA”) with Hudson Global Ventures, LLC (“Hudson”). Under the terms of the Agreement, the Company agreed to sell, and Hudson agreed to purchase, Two Hundred Ninety ( 290 ) shares of Series C Preferred Stock (the “Purchased Shares”) at a price of $ 1,000 per share and a Warrant to purchase up to 41,193 shares of Common Stock. Additionally, pursuant to the Agreement, 40,000 shares of Common Stock were issued to Hudson upon closing for a commitment fee. The Company received $ 250,000 in exchange for the Purchased Shares, Common Stock, and Warrants, net of issuance costs. Designation of Series B Preferred Stock Effective June 26, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series B Preferred Stock with the Secretary of the State of Delaware which designated 787,754 shares of the Company’s authorized and unissued preferred stock as convertible Series B Preferred Stock at a par value of $ 0.00001 per share. 2023 1:15 Stock Split Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date . This was executed to comply with the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $ 1 . Common Stock During the six months ended June 30, 2024, the Company issued 470,482 shares of common stock for services. The fair value of shares issued for services was $ 4,450,919 and was included in general and administrative expenses in the consolidated statements of operations. During the six months ended June 30, 2024, a warrants holder exercised a warrant and acquired 28,487 shares of common stock for $ 16,567 in proceeds (see Note 14). During the six months ended June 30, 2024, an options holder exercised an option and acquired 2,371 shares of common stock for $ 9,840 in proceeds (see Note 15). Special Cash Dividend On March 6, 2024, the Company announced the declaration of a special cash dividend of eight dollars ($ 8.00 ) per share of common stock, payable to stockholders of record as of March 18, 2024, with the dividend being paid on March 22, 2024. The special dividend of $ 12,671,072 (in the aggregate) was paid using a portion of the proceeds from the closing of the sale of the Trxade assets to MMS. On July 9, 2024, the Company announced the declaration of a special cash dividend of one dollar and fifty cents ($ 1.50 ) per share of common stock, payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. The special dividend of $ 2,187,759 was paid using a portion of the proceeds received in May 2024 in connection with the sale of the Trxade assets to MMS. Equity Compensation Awards Each independent member of the Board is to receive an annual grant of restricted common stock of the Company equal to $ 55,000 in value on April 1st of each year (or such date thereafter as the awards are approved by the Board), and valued on such same date, based on the closing sales price on such date (or the first business day thereafter), which restricted stock awards will vest at the rate of 1/4th of such awards over the following four calendar quarters, subject to such directors continued service to the Company. Effective on August 13, 2023, the Board approved the issuance of 24,444 shares of common stock of the Company to each of Mr. Fell and Mr. Peterson (who each at the time of issuance were members of the Board of Directors) for services rendered to the Company during fiscal 2023, which shares were valued at $ 110,000 . The Board also approved the issuance of 14,056 shares of common stock of the Company to Jeff Newell (who, at the time of issuance was a member of the Board of Directors) for services rendered during fiscal 2023, which were valued at $ 63,250 based on the most recent close price of the Company’s common stock on the date approved by the Board. The shares vest at the rate of 1/4th of such shares immediately on the grant date, and 1/4th of such shares on each of October 1, 2023, January 1, 2024 and April 1, 2024, subject to each applicable independent director’s continued service to the Company on such dates. Additionally, the Board approved 10,000 shares with immediate vesting to each Board member to recognize the significant additional work for various financing, sales, acquisitions, operations restructuring. All of the awards discussed above were issued under the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “Plan”) and all restricted stock awards discussed above were evidenced by Restricted Stock Grant Agreements. The Company’s board of directors and stockholders approved an amendment to the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “2019 EIP”) increasing the available shares under the 2019 EIP to 5,000,000 shares of the Common Stock as such common stock existed on July 24, 2024 (see Note 19). 20 NOTE 13 – PREFUNDED AND PRIVATE PLACEMENT WARRANTS On October 4, 2022 the Company entered into a securities purchase agreement (the “ Purchase Agreement ”) with institutional investor (the “Purchaser”) which provided for the sale and issuance by the Company of (i) the Company’s common stock (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) and (iii) warrants (the “Private Placement Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”). On January 4, 2023, the investor exercised the Pre-Funded Warrants for a purchase price of $ 6.02 . The investor was issued the shares on this date. Each Private Placement Warrant has an exercise price of $ 22.50 per share and is exercisable following the Stockholder Approval obtained in December 2022, and will expire on the fifth anniversary of the date on which the Private Placement Warrants became exercisable. The Private Placement Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions, and include full ratchet anti-dilutive rights in the event the Company issues shares of Common Stock or Common Stock equivalents within fifteen months of the initial exercise date, with a value less than the then exercise price of such Private Placement Warrants, subject to certain customary exceptions, and further subject to a minimum exercise price of $ 3.48 per share. The Private Placement Warrants also include certain rights upon ‘fundamental transactions’ as described in the Private Placement Warrants, including allowing the holders thereof to require that the Company re-purchase such Private Placement Warrants at the Black Scholes Value of such securities. NOTE 14 – WARRANTS During the six months ended June 30, 2024, 28,487 warrants to purchase shares of common stock were exercised for a total purchase price of $ 16,567 (see Note 12). The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. There was no compensation cost related to the warrants for the six months ended June 30, 2024, and 2023, respectively. As of June 30, 2024, the Company remeasured the fair value of warrants outstanding at $ 1,631,974 . In connection with remeasurement of warrants, a $ 165,132 and $ 895,021 expense was recognized during the three and six months ended June 30, 2024, respectively, as the change in fair value of warrant liability. The Company’s outstanding and exercisable warrants As of June 30, 2024, are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Exercise Price Contractual Life In Years Intrinsic Value Warrants outstanding as of December 31, 2023 218,729 19.62 3.95 - Warrants granted - - - - Warrants forfeited, expired, cancelled - - - - Warrants exercised ( 28,487 ) 7.14 - - Warrants outstanding as of June 30, 2024 190,242 21.48 3.34 141,926 Warrants exercisable as of June 30, 2024 190,242 21.48 3.34 141,926 21 NOTE 15 – OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 155,556 shares, and the Company’s Second Amended and Restated 2019 Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 133,333 shares) on April 1 st of each calendar year, beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. The administrator as a result of the annual meeting shareholder vote increased the number of shares available to grant to employees under the 2019 incentive plan by 2,000,000. The administrator did not approve an increase in the number of shares covered under the plan as of April 1, 2022. For the six-month period ended June 30, 2024, no options to purchase shares were granted. For the six-month period ended June 30, 2024, 2,371 options to purchase shares of common stock were exercised for $ 9,840 in cash (see Note 12). Total compensation cost related to stock options granted was $ 444 and $ 7,783 for the three months ended June 30, 2024, and 2023, respectively. Total compensation cost related to stock options granted was $ 24,710 and $ 22,217 for the six months ended June 30, 2024 and 2023, respectively. The following table represents stock option activity for the six-month period ended June 30, 2024: SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted- Average Exercise Price Weighted- Average Contractual Life in Years Intrinsic Value Options outstanding as of December 31, 2023 26,229 $ 43.04 3.70 $ - Options exercisable as of December 31, 2023 16,141 60.75 3.64 - Options granted - - - - Options adjusted 72 - - - Options expired - - - - Options exercised ( 2,371 ) 53.29 3.32 - Options outstanding as of June 30, 2024 23,930 40.78 3.18 46,125 Options exercisable as of June 30, 2024 23,930 42.16 2.28 46,125 NOTE 16 – CONTINGENCIES Studebaker Defense Group, LLC In July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein IPS would pay Studebaker a down payment of $ 550,000 and Studebaker would deliver 180,000 boxes of nitrile gloves by August 14, 2020. IPS wired the $ 550,000 to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, the Company filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. At June 30, 2021, the $ 500,000 was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit was filed to collect. 22 On April 13, 2023, a settlement was reached in the Studebaker and IPS legal case. The court found in favor of IPS and ordered Studebaker to pay $ 550,000 to IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 installments until the full amount is paid in full but as of the filing date, no payment has been received by IPS. GSG PPE, LLC On November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $ 630,000 which matured on September 30, 2021 . The note provides for attorney fees and interest in addition to the $ 630,000 . Waxman’s personal guaranty confirmed that GSG owed IPS $ 630,000 . On September 30, 2021, the $ 630,000 was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $ 743,000 which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received additional monthly installment payments as part of the agreement through January 2023. As of June 30, 2024, and through the date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January of 2023. NOTE 17 – LEASES The Company has one operating lease for a corporate office as of June 30, 2024. The following table outlines the details of the leases: SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Lease 3 Initial lease term January 2021 to December 2021 October 2018 to November 2023 October 2023 to September 2026 New initial lease term January 2022 to December 2026 November 2023 to October 2028 Initial recognition of right of use assets at January 1, 2019 $ 534,140 $ 313,301 $ - New initial recognition of right of use assets at December 31, 2021 $ 977,220 $ - $ - New initial recognition of right of use assets at December 31, 2023 $ - $ - $ 351,581 Incremental borrowing rate 10 % 10 % 10 % The Company entered into a new corporate office lease (Lease 1) in January 2022. At inception, the Company determined that the new lease required remeasurement of the lease liability resulting in the increase of the right-of-use asset and the associated lease liability by $ 977,220 . The Company and the Lessor agreed to terminate the lease and vacate the premises in November 2023. The termination resulted in the surrender of the Company’s security deposit of $ 38,500 . The related right-of-use assets of $ 642,887 and lease liabilities of $ 664,992 were removed from the balance sheet as of December 31, 2023. 23 The Company entered into a lease agreement (Lease 2) for the period of October 2018 to November 2023. At inception, management had included the renewal period from November 2023 to November 2028 within the initial recognition of the related right of use assets and lease liabilities, as it was reasonably expected, at the time, that the renewal option would be exercised. The Company determined that the new lease required measurement and recognition of the lease liability and right-of-use assets of $ 313,301 . The lease is classified as an operating lease. No incentives were included in the lease. The Company entered into a new warehouse lease (Lease 3) October 2023. The Company determined that the new lease required measurement and recognition of the lease liability and right-of-use assets of $ 351,581 . The lease is classified as an operating lease. No incentives were included in the lease. In the first quarter of 2024, the Company sold assets and liabilities of Trxade, Inc. and Superlatus. including the related right of use assets and liabilities. The Company has only Lease 2 active and continuing in the condensed consolidated balance sheet as of June 30, 2024. The table below reconciles the fixed component of the undiscounted cash flows for Lease 2 of the first five years and the total remaining years to the lease liabilities recorded in the Consolidated Balance Sheet as of June 30, 2024. SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES Future lease obligations 2024 remaining $ 26,174 2025 53,652 2026 55,261 2027 56,919 2028 48,612 Total minimum lease payments 240,618 Less: effect of discounting ( 47,014 ) Present value of future minimum lease payments 193,604 Less: current obligation under lease 32,608 Long-term lease obligations $ 160,996 For the three months ended June 30, 2024, and 2023, total operating lease expense was $ 12,840 and $ 75,496 , which is included in general and administrative expenses in the condensed consolidated statements of operations, as well as $ 62,656 from discontinued operations, respectively. For the six months ended June 30, 2024, and 2023, total operating lease expense was $ 25,681 and $ 150,992 , which is included in general and administrative expenses in the condensed consolidated statements of operations, as well as $ 125,312 from discontinued operations, respectively. For the three months ended June 30, 2024, and 2023, total short-term lease expense was $ 2,143 and $ 8,511 , which is included in general and administrative expenses in the condensed consolidated statements of operations, respectively. For the six months ended June 30, 2024, and 2023, total short-term lease expense was $ 10,228 and $ 14,039 , which is included in general and administrative expenses in the condensed consolidated statements of operations, respectively. NOTE 18 – SEGMENT REPORTING Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. The Company classifies its business interests into reportable segments which are: ● IPS - Integra Pharma, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales ● Unallocated - Other – corporate overhead expense and discontinued operations. SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Three Months Ended June 30, 2024 Integra Unallocated Total Revenue $ 18,699 $ - $ 18,699 Gross Profit ( 703 ) - ( 703 ) Segment Assets 9,477,347 5,371,187 14,848,533 Segment Profit/Loss ( 346,431 ) ( 1,487,471 ) ( 1,833,902 ) Cost of Sales $ 19,402 $ - $ 19,402 Three Months Ended June 30, 2023 Integra Unallocated Total Revenue $ 366,526 $ - $ 366,526 Gross Profit 67,139 - 67,139 Segment Assets 343,873 5,328,587 5,672,460 Segment Profit/Loss ( 103,219 ) ( 1,871,659 ) ( 1,974,878 ) Cost of Sales $ 299,387 $ 306,962 $ 606,349 Six Months Ended June 30, 2024 Integra Unallocated Total Revenue $ 18,699 $ - $ 18,699 Gross Profit ( 703 ) - ( 703 ) Segment Assets 9,477,347 5,371,187 14,848,533 Segment Profit/Loss ( 585,086 ) 19,997,217 19,412,131 Cost of Sales $ 19,402 $ - $ 19,402 Six Months Ended June 30, 2023 Integra Unallocated Total Revenue $ 842,882 $ - $ 842,882 Gross Profit 123,398 - 123,398 Segment Assets 343,873 5,328,587 5,672,460 Segment Profit/Loss ( 208,086 ) ( 2,444,746 ) ( 2,652,831 ) Cost of Sales $ 719,484 $ 577,535 $ 1,297,019 24 NOTE 19 – SUBSEQUENT EVENTS On July 9, 2024, the Company announced the declaration of a special cash dividend of one dollar and fifty cents ($ 1.50 ) per share of common stock, payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. The special dividend was $ 2,187,759 paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company’s web-based market platform assets. On July 12, 2024, the Company converted 290 shares of Series C Preferred Stock into 52,158 shares of common stock at the election of the holder. On July 25, 2024, the Company entered into and closed an Agreement and Plan of Merger (the “Scienture Merger Agreement”) with MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub I”), MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), and Scienture, Inc., a Delaware corporation (“Scienture”). Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Scienture (the “First Merger”), with Scienture continuing as the surviving entity and a wholly owned subsidiary of the Company, and (ii) Scienture merged with and into Merger Sub II (the “Second Merger” and, together with the First Merger, the “Mergers”), with Merger Sub II continuing as the surviving entity. In connection with the transactions, the Company will change its name from “TRxADE HEALTH, INC.” to “Scienture Holdings, Inc.” and Merger Sub II, as the surviving entity of the Mergers, will change its name from “MEDS Merger Sub II, LLC” to “Scienture LLC”. Scienture is a pharmaceutical company based in Commack, New York, and focuses on developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Scienture is in the process of developing various assets across therapeutics areas, indications and cater to different market segments. As consideration for the Mergers, at the effective time of the First Merger (the “First Effective Time”), the shares of Scienture common stock issued and outstanding immediately prior to the First Effective Time were converted into the right to receive, in the aggregate, (i) 291,555 shares of the Company’s common stock which represents 19.99 % of the number of shares of common stock issued and outstanding immediately prior to the effective time of the First Merger, and (ii) 6,826,713 shares of the Company’s Series X Non-Voting Convertible Preferred Stock, par value $ 0.00001 per share (the “Series X Preferred Stock”), each share of which is convertible into one share of common stock. See below for description of the Series X Preferred Stock. On July 25, 2024, the Company revoked the authorization to issue shares of the Company’s Series A Preferred Stock, par value $ 0.00001 per share (the “Series A Preferred Stock”). Concurrently with revoking the Company’s authority to issue Series A Preferred Stock, the Company authorized the issuance of up to 9,211,246 shares of the Series X Preferred Stock, a new class of preferred stock. All issued and outstanding shares of Scienture, Inc.’s common stock were converted into the right to receive a combination of shares of Series X Preferred Stock and shares of the Common Stock in connection with the Merger. Specifically, former shareholders of Scienture, Inc. collectively have the right to obtain such shareholders’ pro rata share of 291,555 shares of Common Stock and 6,826,713 shares of Series X Preferred Stock. Shares of Common Stock and Series X Preferred Stock will be issued to former stockholders of Scienture, Inc. upon the exchange agent receiving the former stockholder’s executed letter of transmittal and such other documents reasonably required by the exchange agent or the Company. The Certificate of Designation provides that, subject to any beneficial ownership limitations designated by former Scienture, Inc. stockholders, the shares of Series X Preferred Stock will automatically convert into shares of Common Stock at a 1:1 conversion ratio upon the earliest date permitted by the listing rules of the Nasdaq Stock Market following the date that the Company’s stockholders approve the Preferred Stock Conversion (the “Eligible Conversion Date”). Holders of the Series X Preferred Stock may convert, at any time after the Eligible Conversion Date, shares of the Series X Preferred Stock into shares of the Common Stock. Holders of the Series X Preferred Stock are entitled to receive dividends on shares of the Series X Preferred Stock on an as-if-converted-to-Common-Stock basis, without regard to any beneficial ownership limitation described in a letter of transmittal, equal to and in the same form and manner as dividends are paid to holders of the shares of Common Stock. Subject to any requirements of the General Corporation Law of the State of Delaware, the Series X Preferred Stock has no voting rights. The Series X Preferred Stock ranks on parity with shares of Common Stock as to distributions of assets upon liquidation, dissolution, or winding up of the Company. In connection with the consummation of the Mergers, on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board. It has not yet been determined on which committees of the Board either Dr. Hariharan or Dr. Mani will serve. The Company’s board of directors and stockholders approved an amendment to the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “2019 EIP”) increasing the available shares under the 2019 EIP to 5,000,000 shares of the Common Stock as such common stock existed on July 24, 2024. 25 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS General Information This information should be read in conjunction with the interim unaudited financial statements and the notes thereto included in this Quarterly Report on Form 10-Q, and the audited financial statements and notes thereto and “Part II. Other Information – Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contained in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 22, 2024 (the “Annual Report”). Certain capitalized terms used below and otherwise defined below, have the meanings given to such terms in the footnotes to our unaudited consolidated financial statements included above under “Part I – Financial Information” – “Item 1. Financial Statements”. Please see the section entitled “Glossary” in our Annual Report for a list of abbreviations and definitions used throughout this Report. Unless the context requires otherwise, references to the “Company,” “we,” “us,” “our,” and “Trxade”, refer specifically to TRxADE HEALTH, INC. and its consolidated subsidiaries. References to “Q1”, “Q2”, “Q3”, and “Q4” refer to the first, second, third, and fourth quarter, respectively, of the applicable year. Unless otherwise stated or the context otherwise requires, comparisons from one period to another are to the same period of the prior fiscal year. In addition, unless the context otherwise requires and for the purposes of this report only: ● “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; ● “Securities Act” refers to the Securities Act of 1933, as amended. Summary of The Information Contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations Our Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. MD&A is organized as follows: ● Company Overview . Discussion of our business and overall analysis of financial and other highlights affecting us, to provide context for the remainder of MD&A. ● Recent Events . Summary of material transactions occurring during the three and six months ended June 30, 2024. ● Liquidity and Capital Resources . An analysis of changes in our consolidated balance sheets and cash flows and discussion of our financial condition. ● Results of Operations . An analysis of our financial results comparing the three and six months ended June 30, 2024, and 2023. ● Critical Accounting Policies . Accounting estimates that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts. Company Overview The Company owns, as of June 30, 2024, 100% of Trxade, Inc., Integra Pharma Solutions, LLC and Bonum Health, LLC. Through February 16, 2024, Trxade, Inc., operated a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC (“IPS” d.b.a. Trxade Prime), is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS customers include all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. 26 Bonum Health, LLC (“Bonum Health”), was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health Hub” was launched in February 2020; however, the Company does not anticipate installations moving forward. The Company is in the process of dissolving Bonum Health, Inc. and Bonum Health, LLC and expects those entities are each to be dissolved shortly after the date of this Quarterly Report. The Company has begun the process to administratively dissolve Bonum Health. Scienture Merger On July 25, 2024, the Company completed its acquisition of Scienture. As consideration for the Mergers, at the effective time of the First Merger (the “First Effective Time”), the shares of Scienture common stock issued and outstanding immediately prior to the First Effective Time were converted into the right to receive, in the aggregate, (i) 291,555 shares of the Company’s common stock which represents 19.99% of the number of shares of common stock issued and outstanding immediately prior to the effective time of the First Merger, and (ii) 6,826,713 shares of the Company’s Series X Non-Voting Convertible Preferred Stock. Scienture is a New York based, pre-revenue pharmaceutical research company. The Scienture team is a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Scienture’s assets in development are across therapeutics areas, indications and cater to different market segments. Scienture’s mission is to identify, develop and bring to market innovative technology-based products to address unmet medical needs. It’s targeted portfolio consists of short term and long-term opportunities with efficient development, regulatory, and go to market strategies. Superlatus Merger On July 14, 2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”) and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”). On July 31, 2023 , the Company completed its acquisition of Superlatus in accordance with the terms and conditions of the Merger Agreement (the “Superlatus Merger”), pursuant to which the Company acquired Superlatus by way of a merger of the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the Superlatus Merger. Not all of the closing conditions of the Merger Agreement were met. As a result, the Company entered into Amendment No. 1 to the Amended and Restated Agreement and Plan of Merger (the “Amendment”) on January 8, 2024. Under the terms of the Amendment, the merger consideration to the shareholders of Superlatus was adjusted to the aggregate of 136,441 shares of common stock of the Company, representing 19.99% of the total issued and outstanding common stock of the Company after the consummation of the Superlatus Merger and 15,759 shares of Company’s Series B Preferred Stock, with a conversion ratio of 100 shares of Series B Preferred Stock to one share of common stock. At Closing, the value of the common stock was $7.30 per share, resulting in a total value of $12,500,089. Additionally, the shareholders of Superlatus agreed to surrender back to the Company 291,096 shares of the Company’s Series B Preferred Stock. As described below, in March 2024 the Company divested its entire interest in Superlatus. Dispositions On February 16, 2024, the Company, together with Trxade, Inc., and Micro Merchant Systems, Inc. (“MMS”) entered into an asset purchase agreement (the “APA”) under which MMS agreed to purchase for cash substantially all of the assets of Trxade, Inc. On February 16, 2024, the parties consummated the closing of the transactions contemplated by the APA. Trxade, Inc. operated a web-based market platform designed to enable trading among healthcare buyers and sellers of pharmaceuticals, accessories and services. The purchase price paid at closing was $22,660,182. Pursuant to the terms and conditions of the APA, because MMS received $1,600,000 or greater in certain collections from third parties resulting from any products or services sold, or provided, by the business assets and operations acquired from Trxade, Inc. during the period ending on the four-month anniversary of the closing date, Trxade, Inc. was due an additional $7,500,000 payment from MMS. The Company received the $7,500,000 milestone payment in May 2024. On March 5, 2024, the Company entered in a Stock Purchase Agreement (“SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the SPA, the Company sold all of the issued and outstanding stock of Superlatus Inc., to the Buyer. The $1.00 purchase price for the stock was delivered to the Company at the closing, which occurred simultaneously with the execution of the SPA. As a result of the transaction Superlatus ceased to be a subsidiary of the Company, and the rights and assets of Superlatus together with various liabilities and obligations that were specific to Superlatus became rights and obligations of Buyer. 27 Recent Events On May 23, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department indicating that the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic reports with the SEC. The Notice indicates that the Company must, no later than July 22, 2024, submit a plan to regain compliance with respect to the filing requirement. Following receipt of such plan, Nasdaq may grant an extension of up to 180 calendar days from the due date of the Company’s Quarterly Report on Form 10-Q for the period ending March 31, 2024 (the “Form 10-Q”), or until November 18, 2024, for the Company to regain compliance. However, as a result of filing this Form 10-Q, the Company believes it has fully regained compliance with the Nasdaq Listing Rule. On July 25, 2024, the Company entered into and closed an Agreement and Plan of Merger (the “Scienture Merger Agreement”) with MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub I”), MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), and Scienture, Inc., a Delaware corporation (“Scienture”). Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Scienture (the “First Merger”), with Scienture continuing as the surviving entity and a wholly owned subsidiary of the Company, and (ii) Scienture merged with and into Merger Sub II (the “Second Merger” and, together with the First Merger, the “Mergers”), with Merger Sub II continuing as the surviving entity. In connection with the transactions, the Company will change its name from “TRxADE HEALTH, INC.” to “Scienture Holdings, Inc.” and Merger Sub II, as the surviving entity of the Mergers, will change its name from “MEDS Merger Sub II, LLC” to “Scienture LLC”. Scienture is a pharmaceutical company based in Commack, New York, and focuses on developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Scienture is in the process of developing various assets across therapeutics areas, indications and cater to different market segments. Liquidity and Capital Resources Cash Cash was $7,719,993 as of June 30, 2024, compared to $314 as of December 31, 2023. The increase in cash was primarily due to the proceeds in February 2024 and May 2024 related to the disposition of certain assets of Trxade Inc. to MMS as described above. We expect that our future available capital resources will consist primarily of cash generated from operations, remaining cash balances, borrowings, and additional funds raised through sales of debt and/or equity securities. Liquidity Cash, current assets, current liabilities, short term debt and working capital at the end of each period were as follows: June 30, December 31, Percent 2024 2023 Change Change Cash $ 7,719,993 $ 314 $ 7,719,679 2,458,496 % Current assets (excluding cash) $ 4,424,451 $ 2,752,749 $ 1,671,702 61 % Current liabilities $ 2,902,089 $ 11,556,355 $ (8,654,266 ) -75 % Working capital $ 9,242,355 $ (8,803,292 ) $ 18,045,647 -205 % Our principal sources of liquidity have historically been cash provided by operations, sales of business assets and operations from time to time, sales of equity, and borrowings under various debt arrangements. Our principal uses of cash have been for operating expenses, technology development, and acquisitions. We anticipate these uses will continue to be our principal sources of, and uses of, cash in the future. 28 The increase in cash as of June 30, 2024, compared to December 31, 2023, was primarily due to the proceeds received in February 2024 and May 2024 resulting from the disposition of assets of Trxade Inc. to MMS as described above. Special Cash Dividend On March 6, 2024, the Company announced the declaration of a special cash dividend of eight dollars ($8.00) per share of common stock, payable to stockholders of record as of March 18, 2024, with the dividend being paid on March 22, 2024. The special dividend of $12,671,072 was paid using a portion of the proceeds from the closing of the sale of the Company’s Trxade assets. On July 9, 2024, the Company announced the declaration of a special cash dividend of one dollar and fifty cents ($1.50) per share of common stock, payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. The special dividend was $2,187,759 paid using a portion of the proceeds received in May 2024 in connection with the February 2024 sale of the Trxade Inc.’s web-based market platform assets. Liquidity Outlook Cash Explanation Cash Requirements Our primary objectives for the remainder of 2024 are expected to be the integration of Scienture’s assets and operations into our company and the continued implementation of their business plan as well as the continued development and operational expansions on our Trxade Prime platform, and to complete potential strategic transactions of our business-to-consumer subsidiaries, which may include a potential sale, spin-off, fund raising, combination or other strategic transaction, and also include the winding down of such entities. There can be no assurance that our operations will generate significant positive cash flow, or that additional funds will be available to us, through borrowings or otherwise, on favorable terms if required in the future, or at all. We may also raise additional funding in the future through the sale of equity. We estimate our operating expenses and working capital requirements for the next 12 months to be approximately as follows: Projected Expenses from July 2024 to June 2025 Amount General and administrative (1) $ 4,800,000 Total $ 4,800,000 (1) Includes estimated wages and payroll, legal and accounting, marketing, rent and web development. We may require additional funding in the future to implement on our business plan and potentially to expand or complete acquisitions. The sources of this capital are expected to be equity investments and notes payable. Our plan for the next twelve months is to continue using the same marketing and management strategies to promote our Integra Pharma Solutions assets and operations, exploring strategic transactions involving our corporate assets, while also seeking to expand our and Scienture operations organically or through acquisitions, as funding and opportunities arise. In the event we require additional funding, we plan to raise that through the sale of debt or equity, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing stockholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues. We believe that we have adequate cash to implement our plan to operate a business-to-business web-based marketplace focused on the United States pharmaceutical industry. Our core service is designed to bring the nation’s independent pharmacies and accredited national suppliers of pharmaceuticals together to provide efficient and transparent buying and selling opportunities. Cash Flows The following table summarizes our Consolidated Statements of Cash Flows for the following periods: Six Months Ended June 30, Percent 2024 2023 Change Change Net loss from continuing operations $ (8,258,163 ) $ (3,340,976 ) $ (4,917,186 ) 147 % Net cash provided by (used in): Net cash used in operating activities from continuing operations $ (5,197,913 ) $ (1,259,477 ) $ (3,938,435 ) 313 % Net cash (used in) provided by operating activities from discontinued operations $ (769,805 ) $ 656,512 $ (1,426,318 ) -217 % Operating Activities Net cash used in investing activities from continuing operations $ (2,500,000 ) $ (138,875 ) $ (2,361,125 ) 1700 % Net cash provided by investing activities from discontinued operations $ 29,931,815 $ 420,269 $ 29,511,546 7022 % Investing Activities Net cash used in financing activities from continuing operations $ (13,891,011 ) $ (44,024 ) $ (13,846,987 ) 31453 % Net cash used in financing activities from discontinued operations $ (5,000 ) $ - $ (5,000 ) 0 % Financing Activities Net change in cash $ 7,568,085 $ (365,595 ) $ 7,933,681 -2170 % 29 Cash used in operations for the six months ended June 30, 2024, was $5,967,718, compared to cash used in operations for the six months ended June 30, 2023, of $602,965. The increase in cash used in operations for the six months ended June 30, 2024 compared to June 30, 2023, was mainly due to our net loss and cash used in operating assets and liabilities in 2024. Cash provided by investing activities for the six months ended June 30, 2024, was $27,431,815 and cash provided by investing activities was $281,394 for the six months ended June 30, 2023. The increase in cash provided by investing activities is related to the disposition of Trxade, Inc. and Superlatus, Inc., partially offset by investment in securities of $2,500,000. Cash used in financing activities for the six months ended June 30, 2024, was $13,896,011 compared to cash used in financing activities for the six months ended June 30, 2023, which was $44,024. The increase was mainly due to repayment of the net balance of the contingent funding liability of $1,246,346 and payment of dividends of $12,671,072. Results of Operations The following selected consolidated financial data should be read in conjunction with the unaudited consolidated financial statements and the notes to these statements included above. Three Month Period Ended June 30, 2024, compared to Three Month Period Ended June 30, 2023 Three Months Ended June 30, Percent 2024 2023 Change Change Revenues $ 18,699 $ 366,526 $ (347,827 ) -95 % Cost of sales 19,402 299,387 (279,985 ) -94 % Gross (loss) profit (703 ) 67,139 (67,842 ) -101 % Operating expenses: Wage and salary expense 312,049 156,300 155,749 100 % Professional fees 509,136 188,343 320,793 170 % Accounting and legal expense 171,708 124,799 46,909 38 % Technology expense 86,674 27,579 59,095 214 % General and administrative (less stock-based compensation expense) 414,977 162,117 252,860 156 % Warrants and options expense 444 7,783 (7,339 ) -94 % Total operating expenses 1,494,988 666,921 828,066 124 % Change in fair value of warrant liability (165,132 ) (1,448,519 ) 1,283,387 -89 % Interest income 41,031 - 41,031 100 % Interest expense (4,949 ) (180,734 ) 175,785 -97 % Net loss from operations (1,624,741 ) (2,229,035 ) 604,296 -27 % (Loss) income from discontinued operations (209,161 ) 254,157 (463,318 ) -182 % Net (loss) income $ (1,833,902 ) $ (1,974,878 ) $ 140,976 -7 % 30 There are $18,699 in revenues for the three months ended June 30, 2024. Revenues decreased by $347,827, compared to the same period ended June 30, 2023 primarily because of the disposition of the assets and operations of Trxade, Inc. completed in February 2024 which resulted in the Company having fewer revenue generating operations when compared to the comparable period in 2023. For the three-month period ended June 30, 2024, cost of goods sold and gross (loss) profit were $19,402 and $(703), and $299,387 and $67,139, all respectively for the same period in 2023. Gross profit as a percentage of sales was (3.76)% for the three months ended June 30, 2024, compared to 18.32% for the three months ended June 30, 2023. Wages and salary expense increased by $155,749 for the three months ended June 30, 2024 to $312,049 compared to $156,300 for the comparable period in 2023. The increase is primarily due to increase in salary of COO and CEO of IPS during the three months ended June 30, 2024 as compared to the same period in 2023. Professional fees increased by $320,793 to $509,136 compared to $188,343 for the comparable period in 2023. The increase was primarily due to increase in Board members’ fees and consulting expense. Accounting and legal expenses increased by $46,909 for the three months ended June 30, 2024 to $171,708 compared to $124,799 for the comparable period in 2023. The increase is primarily due to more in amount of legal services during the three months ended June 30, 2024 as compared to the same period in 2023. General and administrative expenses (including stock-based compensation expense) increased by $245,521 for the three months ended June 30, 2024, to $415,421 compared to $169,900 for the comparable period in 2023. The increase was mainly due to increase in tax salt expense. Technology expense increased $59,095 for the three months ended June 30, 2024 to $86,674 compared to $27,579 for the comparable period in 2023. The increase was mainly due to increased software expense and software support expense. We had interest expense of $4,949 for the three months ended June 30, 2024, compared to interest expense of $180,734 for the three months ended June 30, 2023. The decrease is due to the sale of note payable of Superlatus, Inc. consequent to sale of its equity interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. We recognized a loss on the change in the fair value of the warrant liability of $165,132 for the three months ended June 30, 2024, compared to a loss of $1,448,519 during the three months ended June 30, 2023. During the three months ended June 30, 2024, the Company incurred a net loss from continuing operations of $1,624,741 compared to a net loss from continuing operations of $2,229,035 for the three months ended June 30, 2023. The decrease in net loss is mainly driven by lower loss on change in fair value of warrant liability in 2024. Net loss from discontinued operations increased by $463,318 to a net loss of $209,161 for the three months ended June 30, 2024, compared to a net income from discontinued operations of $254,157 for the three months ended June 30, 2023. The increase was primarily due to discontinue of operations of Bonum in April 2024 and the results of operations of Bonum shown in discontinued operations. Six Month Period Ended June 30, 2024, compared to Six Month Period Ended June 30, 2023 Six Months Ended June 30, Percent 2024 2023 Change Change Revenues $ 18,699 $ 842,882 $ (824,183 ) -98 % Cost of sales 19,402 719,484 (700,082 ) -97 % Gross (loss) profit (703 ) 123,398 (124,101 ) -101 % Operating expenses: Wage and salary expense 534,644 337,893 196,751 58 % Professional fees 688,689 324,297 364,392 112 % Accounting and legal expense 510,755 373,015 137,740 37 % Technology expense 138,289 52,875 85,414 162 % General and administrative (less stock-based compensation expense) 5,091,316 394,277 4,697,039 1191 % Warrants and options expense 24,266 22,217 2,049 9 % Total operating expenses 6,987,959 1,504,574 5,483,385 364 % Change in fair value of warrant liability (895,021 ) (1,368,628 ) 473,607 -35 % Interest income 103,952 4,198 99,754 2376 % Loss on disposal of asset (374,968 ) (352,244 ) (22,724 ) 100 % Interest expense (103,464 ) (243,126 ) 139,662 -57 % Net loss from operations (8,258,162 ) (3,340,976 ) (4,917,185 ) 147 % Income from discontinued operations 27,670,294 688,145 26,982,149 3921 % Net income (loss) $ 19,412,132 $ (2,652,831 ) $ 22,064,964 -832 % 31 There are $18,699 in revenues for the six months ended June 30, 2024. Revenues decreased by $824,183, compared to the same period ended June 30, 2023 primarily because of the disposition of the assets and operations of Trxade, Inc. completed in February 2024 which resulted in the Company having fewer revenue generating operations when compared to the comparable period in 2023. For the six-month period ended June 30, 2024, cost of goods sold and gross (loss) profit were $19,402 and $(703), and $719,484 and $123,398, all respectively for the same period in 2023. Gross profit as a percentage of sales was (3.76)% for the six months ended June 30, 2024, compared to 14.64% for the six months ended June 30, 2023. Wages and salary expense increased by $196,751 for the six months ended June 30, 2024 to $534,644 compared to $337,893 for the comparable period in 2023. The increase is primarily due to increase in salary of COO and CEO of IPS during the six months ended June 30, 2024 as compared to the same period in 2023. Professional fees increased by $364,392 to $688,689 compared to $324,297 for the comparable period in 2023. The increase was primarily due to increase in Board members’ fees and consulting expense. Accounting and legal expenses increased by $137,740 for the six months ended June 30, 2024 to $510,755 compared to $373,015 for the comparable period in 2023. The increase is primarily due to increase in amount of legal services during the six months ended June 30, 2024 as compared to the same period in 2023. General and administrative expenses (including stock-based compensation expense) increased by $4,699,088 for the six months ended June 30, 2024, to $5,115,582 compared to $416,494 for the comparable period in 2023. The increase was mainly due to shares issued for services at fair value of $4,450,919 and increase in tax salt expense. Technology expense increased by $85,414 for the six months ended June 30, 2024 to $138,289 compared to $52,875 for the comparable period in 2023. The increase was mainly due to increased software expense and software support expense. We had interest expense of $103,464 for the six months ended June 30, 2024, compared to interest expense of $243,126 for the six months ended June 30, 2023. The decrease is due to the sale of note payable of Superlatus, Inc. consequent to sale of its equity interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. We recognized a loss on the change in the fair value of the warrant liability of $895,021 for the six months ended June 30, 2024, compared to a loss of $1,368,628 during the six months ended June 30, 2023. During the six months ended June 30, 2024, the Company incurred a net loss from continuing operations of $8,258,162 compared to a net loss from continuing operations of $3,340,976 for the six months ended June 30, 2023. The increase in net loss is mainly driven by stock compensation in 2024. Net income from discontinued operations increased by $26,982,149 to a net income of $27,670,294 for the six months ended June 30, 2024, compared to a net income from discontinued operations of $688,145 for the six months ended June 30, 2023. The increase was primarily due to the disposal of Trxade, Inc., partially offset by loss on disposal of Superlatus, Inc. during the six months ended June 30, 2024. Critical Accounting Policies Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of net sales and expenses for each period. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. 32 Revenue Recognition In general, the Company accounts for revenue recognition in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers.” Integra Pharma Solutions, LLC (“IPS”) is a licensed wholesaler of brand, generic and non-drug products to Customers. Integra LLC takes orders for products, creates invoices for each order and recognizes revenue at the time the Customer receives the product. Customer returns are not material. Step One: Identify the contract with the Customer – Integra LLC requires that an application and a credit card for payment be completed by the Customer prior to the first order. Each transaction is evidenced by an order form sent by the Customer and an invoice for the product is sent by Integra LLC. The collection is probable based on the application and credit card information provided prior to the first order. Step Two: Identify the performance obligations in the contract – Each order is distinct and evidenced by the shipping order and invoice. Step Three: Determine the transaction price – The consideration is variable if product is returned. The variability is determined based on the return policy of the product manufacturer. There are no sales or volume discounts. The transaction price is determined at the time of the order evidenced by the invoice. Step Four: Allocate the transaction price – There is no difference between contract price and “stand-alone selling price”. Step Five: Recognize revenue when or as the entity satisfies a performance obligation – The Revenue is recognized when the Customer receives the product. The Urgent Company, Inc., was wholly-owned subsidiary, is a retail and distribution provider of prepackaged, prepared foods. Subsequent to December 31, 2023, we divested our interest in The Urgent Company, Inc. 33 Stock-Based Compensation The Company accounts for stock-based compensation to employees in accordance with ASC 718, “Compensation-Stock Compensation”. ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant date fair value of the award and to recognize it as compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period. Stock option forfeitures are recognized at the date of employee termination. Effective January 1, 2019, the Company adopted ASU 2018-07 for the accounting of share-based payments granted to non-employees for goods and services. Recently Issued Accounting Standards For more information on recently issued accounting standards, see “NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION”, to the Notes to Consolidated Financial Statements included herein under “PART I. - ITEM 1. FINANCIAL STATEMENTS”. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1). ITEM 4. CONTROLS AND PROCEDURES Disclosure Controls and Procedures Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, as appropriate, in order to allow timely decisions in connection with required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal accounting/financial officer), Mr. Ajjarapu and Mr Patel, respectively, as of June 30, 2024, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that as of June 30, 2024, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed in our reports filed with the SEC pursuant to the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures. 34 Limitations on the Effectiveness of Controls Management of the Company, including its Chief Executive Officer and its Chief Financial Officer, does not expect that the Company’s disclosure controls and procedures or its internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Furthermore, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons or by the collusion of two or more persons. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of the effectiveness of controls to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Changes in Internal Control Over Financial Reporting There have not been any changes in our internal control over financial reporting during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our workforce operated primarily in a work from home environment. While pre-existing controls were not specifically designed to operate in our current work-from-home operating environment, we do not believe that such work-from-home actions have had a material adverse effect on our internal controls over financial reporting. We have continued to re-evaluate and refine our financial reporting process to provide reasonable assurance that we could report our financial results accurately and timely. 35 PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS In the ordinary course of business, we may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We believe the ultimate resolution of any such current proceeding will not have a material adverse effect on our continued financial position, results of operations or cash flows. Such current litigation or other legal proceedings are described in, and incorporated by reference in, this “ITEM 1. LEGAL PROCEEDINGS” of this Quarterly Report on Form 10-Q from, “PART I – ITEM 1. FINANCIAL STATEMENTS” in the Notes to Consolidated Financial Statements in “NOTE 16 – CONTINGENCIES”. The Company believes that the resolution of currently pending matters will not individually or in the aggregate have a material adverse effect on our financial condition or results of operations. However, assessment of the current litigation or other legal claims could change in light of the discovery of facts not presently known to the Company or by judges, juries or other finders of fact, which are not in accord with management’s evaluation of the possible liability or outcome of such litigation or claims. Additionally, the outcome of litigation is inherently uncertain. If one or more legal matters were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s financial condition and operating results for that reporting period could be materially adversely affected. ITEM 1A. RISK FACTORS There have been no material changes from the risk factors previously disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 22, 2024 (the “Form 10-K”), and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC on June 26, 2024 (“Form 10-Q”), in each case under the heading “Risk Factors”, except for the risks inherent in the assets and operations of Scienture that pertain to the Company after the completion of the merger transaction completed in July 2024 and as set forth below, and investors should review the risks provided in the Form 10-K, Form 10-Q and below, prior to making an investment in the Company. The business, financial condition and operating results of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in the Form 10-K and the Form 10-Q and below, any one or more of which could, directly or indirectly, cause the Company’s actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect the Company’s business, financial condition, operating results and stock price. The Company’s stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger. The Company and Scienture completed a merger transaction on July 25, 2024 as generally described in this report (and other reports and filings we have filed with the SEC), and, if the combined company is unable to realize the full strategic and financial benefits currently anticipated from the merger, the Company’s stockholders will have experienced dilution of their ownership interests in the Company without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the merger. 36 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Recent Sales of Unregistered Securities During the six months ended June 30, 2024, the Company issued 470,482 shares of common stock for services. The Company relied on the exemption from registration set forth in Section 4(a)(2) of the Securities Act for this issuance. On July 12, 2024, the Company converted 290 shares of Series C Preferred Stock into 52,158 shares of common stock at the election of the holder. As consideration for the Mergers, at the effective time of the First Merger (the “First Effective Time”), the shares of Scienture common stock issued and outstanding immediately prior to the First Effective Time were converted into the right to receive, in the aggregate, (i) 291,555 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) which represents 19.99% of the number of shares of Common Stock issued and outstanding immediately prior to the effective time of the First Merger, and (ii) 6,826,713 shares of the Company’s Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the “Series X Preferred Stock”), each share of which is convertible into one share of Common Stock. In each case, the issuance did not involve a public offering and was made without general solicitation or general advertising, and the recipient of the shares was an accredited investor. Purchases of Equity Securities by the Issuer and Affiliated Purchasers The Company repurchased no shares of common stock during the first two quarters of 2024. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES None. ITEM 5. OTHER INFORMATION (a) During the quarter ended June 30, 2024, there was no information required to be disclosed in a report on Form 8-K which was not disclosed in a report on Form 8-K. (b) During the quarter ended June 30, 2024, there were no material changes to the procedures by which stockholders may recommend nominees to our board of directors. 37 ITEM 6. EXHIBITS Exhibit No. Description 31.1* Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). * Filed herewith. ** Furnished herewith. 38 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TRxADE HEALTH, INC. By: /s/ Suren Ajjarapu Suren Ajjarapu Chief Executive Officer (Principal Executive Officer) Date: August 9, 2024 By: /s/ Prashant Patel Prashant Patel Interim Chief Financial Officer (Principal Accounting/Financial Officer) Date: August 9, 2024 39